Need Help? Contact Us

Leading in minimally invasive therapies for arterial disease, venous disease and cancer

From severe leg pain to marathon runner

From severe leg pain to marathon runner

The VICI VENOUS STENT™ provided almost immediate relief and improvement for Kathryn – taking her from barely being able to walk to completing a marathon.

Watch her story

 

Delivering Meaningful Innovation

Advancing the Treatment of Arterial Disease.  Over 200M patients around the world suffer from Peripheral Arterial Disease (PAD) with less than 1% receiving an intervention. We’ve built a strong portfolio of products to serve this market and are uniquely positioned to provide physicians and hospital systems with a full tool box of solutions to treat patients.

Venous Therapies. Our venous portfolio offers a category-leading breadth of venous technologies including: venous stents, endovenous chemical ablation, ultrasound assisted clot dissolution devices, mechanical thrombectomy, bioconvertable inferior vena cava filter (IVC) and imaging catheters.

Tumor-Tackling Technologies. Our interventional oncology portfolio includes embolization technologies, TheraSphere™ Y90 transarterial radioembolization treatment, and ablation technologies, all designed to prevent growth and cause tumor necrosis.

Conditions We Treat

  • Peripheral Artery Disease
  • Deep Vein Thrombosis (DVT)
  • Critical Limb Ischemia
  • Superficial Venous Disease
  • Pulmonary Embolism (PE)
  • Liver Cancer
  • Kidney Cancer

Products and Solutions We Offer

  • Peripheral Balloons and Stents
  • Drug-Eluting Technologies
  • Crossing Technology
  • Guidewires & Accessories
  • Venous Obstruction
  • Clot Management
  • Imaging
  • Venous Insufficiency
  • Embolization
  • Cancer Therapies
  • Tumor Ablation & Treatments
  • Access Delivery

Product spotlights

Spectra WaveWriter™
The Eluvia™ Drug-Eluting Vascular Stent System is specifically developed for the treatment of peripheral artery disease (PAD). The Eluvia stent utilizes a drug-polymer combination to offer sustained release of the drug paclitaxel for a one-year timeframe, designed to prevent tissue regrowth that might otherwise block the stented artery. The Eluvia stent was approved by the FDA based on findings from the IMPERIAL trial, in which the Eluvia stent demonstrated superior results in the first superficial femoral artery head-to-head drug-eluting stent trial.
Spectra WaveWriter™
TheraSphere™ is a radioembolization treatment for patients diagnosed with primary liver cancer and metastatic liver cancer. It is a targeted therapy that consists of millions of glass microspheres containing radioactive yttrium-90. TheraSphere™ is delivered into the hepatic artery to selectively target and destroy tumor cells while minimizing distribution and impact to normal tissue. The radioactive microspheres continue to deliver radiation to the tumor over the course of several weeks after treatment.
Spectra WaveWriter™
The EKOS Acoustic Pulse Thrombolysis™ System, the first endovascular device cleared by the FDA for the treatment of PE, which is designed to leverage targeted ultrasonic waves in combination with clot-dissolving drugs in the treatment of peripheral thrombus.
 

Sources

1. Fowkes, F, et. al., The Lancet, Volume 382, Issue 9901, 1329-1340

2. Gerotziafas GT, et. al., Curr Opin Pulm Med. 2004; 10:356-365; Cohen AT, et.al., Thromb Haemost. 2007 Oct;98(4):756-64

3. International Association of Cancer Registries; GLOBOCAN Database: http://gco.iarc.fr/

Top